SCHEMBL15060795

SCHEMBL15060795

CCOCCn1c(C=O)nc2cc(Cl)c(Oc3ccc(F)cc3)cc21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 3/20 0.34
MTNR1B P49286 3/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 1/20 0.34
LMNA P02545 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SCN9A Q15858 2/20 0.33
MMP14 P50281 2/20 0.32
MMP13 P45452 1/20 0.32
VDR P11473 1/20 0.32
MEN1 O00255 1/20 0.32
TSHR P16473 1/20 0.32
KMT2A Q03164 1/20 0.32
PDE5A O76074 1/20 0.32
HAT1 O14929 1/20 0.32
KAT7 O95251 1/20 0.32
EP300 Q09472 1/20 0.32
RBBP7 Q16576 1/20 0.32
CREBBP Q92793 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18404401 0.91 LMNA (0.41) MTNR1AMTNR1BKDM4EHSD17B10LMNA
SCHEMBL12210252 0.90 KDM4E (0.35) KDM4EHSD17B10LMNARAB9ASMN1; SMN2
SCHEMBL18404249 0.88 SCN9A (0.34) KDM4EHSD17B10LMNARAB9ASMN1; SMN2
SCHEMBL13273917 0.85 PPARG (0.41) KDM4EHSD17B10LMNARAB9ASMN1; SMN2
SCHEMBL13273928 0.84 HSP90AA1 (0.37) KDM4EHSD17B10LMNASMN1; SMN2VDR
SCHEMBL13273926 0.79 HAT1 (0.39) MTNR1AMTNR1BKDM4EHSD17B10LMNA
SCHEMBL13274129 0.78 HAT1 (0.36) MTNR1AMTNR1BKDM4EHSD17B10LMNA
SCHEMBL12210155 0.78 HAT1 (0.36) MTNR1AMTNR1BKDM4EHSD17B10LMNA
SCHEMBL18404505 0.78 POLB (0.35) MTNR1AMTNR1BKDM4ELMNAVDR
SCHEMBL15060784 0.78 PDE5A (0.37) KDM4EHSD17B10SMN1; SMN2MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303535-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2013-11-14 US disclosed
US-20130303535-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Sumitomo Pharma Co., Ltd. (JP) 2013-11-14 US disclosed
US-8471038-B2 Bicyclic heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-06-25 US disclosed
US-8471038-B2 Bicyclic heterocyclic compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-06-25 US disclosed
US-20110294804-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-12-01 US disclosed
US-20110294804-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110294804-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND OPRL1, SCN1B, OPRD1 MTNR1A 280/4885MTNR1B 162/4885KDM4E 2976/4885
US-20130303535-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND OPRL1, SCN1B, OPRD1 MTNR1A 280/4885MTNR1B 162/4885KDM4E 2976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.